HIF1A and glioblastoma: In contrast, we found that HIF-1α downregulation, but not HIF-2α downregulation, significantly sensitized these GBM cells to temozolomide, i.e., > 47% and 48% in U251 and U87, respectively (Fig. 4e, f).